Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Predator-Prey Interactions02:39

Predator-Prey Interactions

21.1K
Predators consume prey for energy. Predators that acquire prey and prey that avoid predation both increase their chances of survival and reproduction (i.e., fitness). Routine predator-prey interactions elicit mutual adaptations that improve predator offenses, such as claws, teeth, and speed, as well as prey defenses, including crypsis, aposematism, and mimicry. Thus, predator-prey interactions resemble an evolutionary arms race.
21.1K
Van der Waals Interactions01:24

Van der Waals Interactions

70.8K
Atoms and molecules interact with each other through intermolecular forces. These electrostatic forces arise from attractive or repulsive interactions between particles with permanent, partial, or temporary charges. The intermolecular forces between neutral atoms and molecules are ion–dipole, dipole–dipole, and dispersion forces, collectively known as van der Waals forces.
70.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

836
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
836
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

969
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
969
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Quality and Suitability of Self-Collected Vaginal and Urine Samples for Human Papillomavirus Testing: A Prospective Matched Study.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Interventions for patients with prostate cancer on active surveillance: a narrative review.

BJU international·2025
Same author

Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.

British journal of cancer·2025
Same author

Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States.

Journal of the National Cancer Institute·2024
Same author

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.

JAMA·2024
Same author

A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention Trial.

Nutrients·2024
Same journal

Sociodemographic trends in prostate cancer: Insights from the all of Us research program.

JNCI cancer spectrum·2026
Same journal

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

JNCI cancer spectrum·2026
Same journal

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

JNCI cancer spectrum·2026
Same journal

Response to bates.

JNCI cancer spectrum·2026
Same journal

RE: Rural-urban disparities and trends in cancer screening: an analysis of Behavioral Risk Factor Surveillance System data (2018-2022).

JNCI cancer spectrum·2026
Same journal

Pandemic-era increases in late-stage pediatric cancer diagnoses, 2020-2022.

JNCI cancer spectrum·2026
See all related articles

Related Experiment Video

Updated: Jan 21, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.8K

Prognosis vs Treatment Interaction.

Jack Cuzick1

  • 1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

JNCI Cancer Spectrum
|July 31, 2019
PubMed
Summary
This summary is machine-generated.

Biomarkers for nontargeted therapies are valuable even without treatment interaction. Prognostic biomarkers offer greater absolute benefit to patients with poorer prognoses, regardless of relative treatment effects.

More Related Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.9K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.7K

Related Experiment Videos

Last Updated: Jan 21, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.8K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.9K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.7K

Area of Science:

  • Biomarker research
  • Clinical trial design
  • Nontargeted therapy

Background:

  • A common misconception is that biomarkers must demonstrate treatment interaction to guide therapy selection.
  • Established clinical markers like tumor size often lack direct treatment interaction but are clinically useful.
  • This principle extends to biomarkers, particularly in the context of nontargeted therapeutic strategies.

Purpose of the Study:

  • To challenge the notion that treatment interaction is a prerequisite for biomarker utility in nontargeted therapies.
  • To highlight the importance of prognostic information provided by biomarkers.
  • To explain how prognostic biomarkers can guide treatment decisions by focusing on absolute benefit.

Main Methods:

  • Conceptual analysis and argumentation.
  • Review of existing clinical marker utility.
  • Application of principles to biomarker-guided nontargeted therapy.

Main Results:

  • Biomarker utility is not solely dependent on demonstrating a treatment interaction effect.
  • Prognostic information from biomarkers is crucial for nontargeted treatments.
  • Absolute treatment benefit, not just relative benefit, determines clinical impact.

Conclusions:

  • Biomarkers can guide treatment decisions based on prognosis, even without a direct interaction with the treatment.
  • For nontargeted therapies, the absolute benefit derived from a prognostic biomarker is more critical than relative treatment effects.
  • Poor prognosis patients gain a larger absolute benefit from treatments when guided by prognostic biomarkers, irrespective of interaction effects.